title: The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients.
abstract: Mycophenolate mofetil is a potent inhibitor of de novo guanine nucleotide synthesis that selectively blocks lymphocyte proliferative responses. In animal models, mycophenolate mofetil has been shown to prolong allograft survival, reverse ongoing rejection, and induce strain-specific tolerance. To assess the safety and efficacy of mycophenolate mofetil in cardiac transplantation, 30 recipients with mild rejection were enrolled in an 8-week phase I trial. Mycophenolate mofetil in doses from 500 to 3000 mg/day orally was substituted for azathioprine, while baseline cyclosporine levels and corticosteroid doses were maintained. Rejection resolved in the majority of patients, with a significant decrease in mean biopsy score. By protocol, mycophenolate mofetil was discontinued in 4 patients due to persistent mild rejection, and in 4 patients due to progression to moderate rejection. The rate of progression to moderate rejection compared favorably with that observed in patients with mild rejection maintained on azathioprine without augmentation of immunosuppression. Significant increases were observed in hematocrit, total white blood cell count, and absolute neutrophil count. Absolute lymphocyte count remained unchanged. No nephrotoxicity or hepatotoxicity was observed. Gastrointestinal side effects prompted discontinuation of mycophenolate mofetil in one patient. Two major infections occurred. Mycophenolate mofetil remained well tolerated during long-term maintenance immunosuppression, with a rate of rejection similar to that in patients receiving azathioprine. We conclude that mycophenolate mofetil is safe and well tolerated in cardiac transplant recipients, is less myelosuppressive than azathioprine, and appears to be at least equipotent to azathioprine.
authors.affiliation: University of Utah Medical Center, LDS Hospital 84132.
authors.forename: R D
authors.initials: RD
authors.lastname: Ensley
authors.forename: M R
authors.initials: MR
authors.lastname: Bristow
authors.forename: S L
authors.initials: SL
authors.lastname: Olsen
authors.forename: D O
authors.initials: DO
authors.lastname: Taylor
authors.forename: E H
authors.initials: EH
authors.lastname: Hammond
authors.forename: J B
authors.initials: JB
authors.lastname: O'Connell
authors.forename: D
authors.initials: D
authors.lastname: Dunn
authors.forename: L
authors.initials: L
authors.lastname: Osburn
authors.forename: K W
authors.initials: KW
authors.lastname: Jones
authors.forename: R S
authors.initials: RS
authors.lastname: Kauffman
mesh_terms: D000328:Adult; D001706:Biopsy; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000473:pathology; D016027:Heart Transplantation / Q000473:pathology / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000633:toxicity*; D008111:Liver Function Tests; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity
chemical_list: D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid